AmDen Pharmaceuticals Denmark ApS: Financial statements 2023
CVR: 42045403
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
AmDen Pharmaceuticals Denmark ApS (CVR 42045403) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -5,000 and a net result of DKK -4,574 compared with DKK -14,929 the year before. Equity in the 2023 report amounted to DKK 30,497. The solvency ratio was 82.4%. The company had 1 employee in the financial year.
- Gross Profit
- DKK -5,000
- Profit/Loss
- DKK -4,574
- Equity
- DKK 30,497
- Total Assets
- DKK 36,997
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -5K | -5K | 30K | 1 |
| 2022 | - | -7K | -15K | 35K | 1 |
| 2021 | - | 750K | 584K | 624K | 1 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
AmDen Pharmaceuticals Denmark ApS has published its annual report for 2022. Gross profit came to DKK -6,788, and the net result was DKK -14,929.
About AmDen Pharmaceuticals Denmark ApS
AmDen Pharmaceuticals Denmark ApS is a Danish company of the type Anpartsselskab based in Køge, founded in 2021. The company is registered under the industry Andre liberale, videnskabelige og tekniske tjenesteydelser i.a.n.. The management consists of Flemming Dyremose and Mikael Søndergaard Thomsen. The company is owned by Thomsen Pharma ApS and Flandy Holding ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -7,514 and a net result of DKK -4,907 compared with DKK -7,596 the year before. Equity in the 2025 report amounted to DKK 17,994.